Genesee Capital Advisors LLC Makes New Investment in Eli Lilly and Company (NYSE:LLY)

Genesee Capital Advisors LLC bought a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 428 shares of the company’s stock, valued at approximately $250,000.

Other large investors also recently modified their holdings of the company. Simon Quick Advisors LLC lifted its stake in Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after purchasing an additional 278 shares during the last quarter. Clear Harbor Asset Management LLC bought a new stake in Eli Lilly and Company during the 4th quarter worth $363,000. Liontrust Investment Partners LLP bought a new stake in Eli Lilly and Company during the 3rd quarter worth $8,326,000. WASHINGTON TRUST Co increased its holdings in Eli Lilly and Company by 16.5% in the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock worth $11,013,000 after purchasing an additional 2,671 shares in the last quarter. Finally, Armstrong Fleming & Moore Inc bought a new position in Eli Lilly and Company in the second quarter valued at about $357,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research note on Wednesday, February 21st. BMO Capital Markets lifted their price objective on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Finally, Morgan Stanley increased their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $712.05.

Insider Buying and Selling at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 1,180 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $645.60, for a total transaction of $761,808.00. Following the completion of the transaction, the insider now directly owns 99,542,630 shares in the company, valued at approximately $64,264,721,928. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders sold 133,785 shares of company stock worth $86,537,034. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $2.44 during mid-day trading on Thursday, reaching $759.54. 1,594,381 shares of the company were exchanged, compared to its average volume of 3,112,412. The company’s 50 day moving average price is $760.09 and its 200 day moving average price is $651.25. Eli Lilly and Company has a 52 week low of $363.33 and a 52 week high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The stock has a market capitalization of $721.68 billion, a PE ratio of 130.96, a PEG ratio of 1.71 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same period last year, the firm earned $2.09 earnings per share. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. Sell-side analysts forecast that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.